207 related articles for article (PubMed ID: 30817035)
1. Anaphylaxis after Elosulfase A infusion: Omalizumab as coadjuvant for enzyme replacement therapy desensitization.
Arroabarren E; Aznal E; Anda M; Sanchez-Valverde F
Pediatr Allergy Immunol; 2019 Jun; 30(4):491-494. PubMed ID: 30817035
[No Abstract] [Full Text] [Related]
2. Successful desensitization of elosulfase alfa-induced anaphylaxis in a pediatric patient with Morquio syndrome.
Guvenir H; Dibek Misirlioglu E; Capanoglu M; Buyuktiryaki B; Unal O; Toyran M; Kocabas CN
J Allergy Clin Immunol Pract; 2017; 5(4):1156-1157. PubMed ID: 28689831
[No Abstract] [Full Text] [Related]
3. Shortened desensitization leading to a 2-year enzyme replacement therapy with elosulfase alfa.
Bekis Bozkurt H; Karakurt T; Cavkaytar O; Arga M
Ann Allergy Asthma Immunol; 2021 Aug; 127(2):261-262. PubMed ID: 33992778
[No Abstract] [Full Text] [Related]
4. Immunogenicity of Elosulfase Alfa, an Enzyme Replacement Therapy in Patients With Morquio A Syndrome: Results From MOR-004, a Phase III Trial.
Schweighardt B; Tompkins T; Lau K; Jesaitis L; Qi Y; Musson DG; Farmer P; Haller C; Shaywitz AJ; Yang K; O'Neill CA
Clin Ther; 2015 May; 37(5):1012-1021.e6. PubMed ID: 25487082
[TBL] [Abstract][Full Text] [Related]
5. Successful desensitization of a patient with Fabry disease with agalsidase beta (Fabrazyme) anaphylaxis after omalizumab pretreatment.
DuBuske I; Schmidlin K; Bernstein JA
Ann Allergy Asthma Immunol; 2021 Jan; 126(1):96-98. PubMed ID: 32866621
[No Abstract] [Full Text] [Related]
6. Successful Desensitization to Oxaliplatin After a Single Initial Dose of Omalizumab in a Patient With Elevated IgE Levels.
Penella J; Quan P; Carvallo A; Chopitea A; Sala P; García Del Barrio MA; Gastaminza G; Goikoetxea MJ
J Investig Allergol Clin Immunol; 2020; 30(4):293-295. PubMed ID: 32101174
[No Abstract] [Full Text] [Related]
7. Usefulness of Omalizumab in Rapid Drug Desensitization in Patients With Severe Anaphylaxis Induced by Carboplatin: Open Questions.
Sánchez-Morillas L; Casado Herráez A; Rubio-Perez M; Robledo Echarren T; González Gutiérrez ML; Cimarra M; Vázquez Cortés S; Cerecedo I; Fernández-Rivas M
J Investig Allergol Clin Immunol; 2020; 30(4):298-300. PubMed ID: 32101175
[No Abstract] [Full Text] [Related]
8. Is premedication a necessity before galsulfase replacement therapy?
Ercan N; Bostanci IB; Ozmen S; Ertugrul A
Ann Allergy Asthma Immunol; 2016 Aug; 117(2):200-2. PubMed ID: 27346567
[No Abstract] [Full Text] [Related]
9. Successful sebelipase alfa desensitization in a pediatric patient.
Kulhas Celik I; Kucukcongar Yavas A; Unal Uzun O; Siyah Bilgin B; Dibek Misirlioglu E; Gunduz M
J Allergy Clin Immunol Pract; 2019 Feb; 7(2):732-733. PubMed ID: 30053591
[No Abstract] [Full Text] [Related]
10. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
Kim J; Park MR; Kim DS; Lee JO; Maeng SH; Cho SY; Han Y; Ahn K; Jin DK
Allergy; 2013 Jun; 68(6):796-802. PubMed ID: 23621439
[TBL] [Abstract][Full Text] [Related]
11. Clindamycin anaphylaxis confirmed by in vivo and in vitro testing.
Ebo DG; Mertens C; Braes M; Mennes I; Bridts CH; Sabato V
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):331-333. PubMed ID: 29940315
[No Abstract] [Full Text] [Related]
12. The Use of Omalizumab in Food Oral Immunotherapy.
Labrosse R; Graham F; Des Roches A; Bégin P
Arch Immunol Ther Exp (Warsz); 2017 Jun; 65(3):189-199. PubMed ID: 27628022
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab may facilitate drug desensitization in patients failing standard protocols.
Gemici Karaaslan HB; Karabag Yilmaz E; Gulmez R; Canpolat N; Kiykim A; Cokugras HC
Pediatr Allergy Immunol; 2022 May; 33(5):e13783. PubMed ID: 35616895
[No Abstract] [Full Text] [Related]
14. Successful Elosulfase Alfa Desensitization Protocol in a Patient With Morquio A Syndrome.
Díaz Vidal VC; Gillispie A; Aranda C; Anvari S
Pediatrics; 2022 Feb; 149(2):. PubMed ID: 35059725
[TBL] [Abstract][Full Text] [Related]
15. Immune modulation in a patient with Morquio syndrome treated with enzyme replacement therapy.
Sun A; Alshuaibi W; Petroni D; Skoda-Smith S; Goldberg MJ; Hale S
J Allergy Clin Immunol Pract; 2018; 6(5):1749-1751. PubMed ID: 29426755
[No Abstract] [Full Text] [Related]
16. Basophil Activation Test is a Relevant Biomarker of the Outcome of Rapid Desensitization in Platinum Compounds-Allergy.
Giavina-Bianchi P; Galvão VR; Picard M; Caiado J; Castells MC
J Allergy Clin Immunol Pract; 2017; 5(3):728-736. PubMed ID: 28034549
[TBL] [Abstract][Full Text] [Related]
17. Anaphylaxis due to progesterone hypersensitivity successfully treated with omalizumab.
Heffler E; Fichera S; Nicolosi G; Crimi N
J Allergy Clin Immunol Pract; 2017; 5(3):852-854. PubMed ID: 28258855
[No Abstract] [Full Text] [Related]
18. Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study.
Long B; Tompkins T; Decker C; Jesaitis L; Khan S; Slasor P; Harmatz P; O'Neill CA; Schweighardt B
Clin Ther; 2017 Jan; 39(1):118-129.e3. PubMed ID: 27955919
[TBL] [Abstract][Full Text] [Related]
19. Drug-Induced Paradoxical Vocal Fold Motion.
Garcia-Neuer M; Lynch DM; Marquis K; Dowdall J; Castells M; Sloane DE
J Allergy Clin Immunol Pract; 2018; 6(1):90-94. PubMed ID: 29037819
[TBL] [Abstract][Full Text] [Related]
20. Clinical aspects of oral immunotherapy for the treatment of allergies.
Yanagida N; Sato S; Ebisawa M
Semin Immunol; 2017 Apr; 30():45-51. PubMed ID: 28780220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
